Replimune reports fiscal 2026 results and BLA progress for RP1
Replimune (NASDAQ:REPL) reported fiscal 2026 results with a net loss of $313.9 million, research and development expenses of $221.2 million, and selling, general and administrative expenses of $98.7 million.


_1429853_640x360_2505037379572-640x360.webp&w=3840&q=75)
_1429851_640x360_2505035843852-640x360.webp&w=3840&q=75)

_1429843_640x360_2505035843839-640x360.webp&w=3840&q=75)





